

ASX ANNOUNCEMENT

29 June 2020



STRATEGIC SHIPMENT EXPORTED TO THE UK

1,000+ UNITS EXPORTED TO THE UK

Highlights:

- 🌿 Little Green Pharma exports 1,000+ units of medicinal cannabis oil under new consignment sales agreement with LYPHE
- 🌿 Strategically important shipment demonstrates UK supply pathway for potential future sales growth
- 🌿 LYPHE is Astral Health's parent company and currently writes over half of all new prescriptions for medicinal cannabis in the UK

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce the export of the first commercial quantity of medicinal cannabis oils to the UK. The shipment to LYPHE Group Limited ("LYPHE") was made under a consignment sales agreement for 1,000+ units of medicinal cannabis oil ("LYPHE Agreement").

LYPHE is the parent company of Astral Health, to whom LGP delivered a pathfinder shipment in April 2020 (ASX announcement dated 15 April 2020). LYPHE has developed a patient-access and distribution ecosystem which positions the company as a leader in the UK's rapidly expanding medicinal cannabis market.

Under the LYPHE Agreement, LYPHE will prescribe and dispense LGP medicinal cannabis products to patients at its clinics, while reporting real-world anonymised data investigating efficacy, safety, quality of life, and patient-reported outcomes to LGP.

The shipment is strategically important for LGP as it serves to demonstrate a viable commercial channel into the UK and represents a key step towards LGP's goal of serving growing patient demand for medicinal cannabis in the UK and the EU. While LGP anticipates the realised sales price for the units will be higher than its Australian wholesale pricing, the Company does not expect the potential sales revenue generated by this shipment to be financially material.

LGP also anticipates receiving its expanded Cultivation and Production Permit in the near term, which will provide significant additional cultivation capacity to help LGP meet UK and EU market demand. LGP anticipates making its first export of medicinal cannabis products to Germany by Q4CY2020.

ENDS



BY ORDER OF THE BOARD



Craig Basson

Company Secretary

For further information please contact:

Craig Basson, Company Secretary
Little Green Pharma

E: craig@lgpharma.com.au

T: +61 8 6280 0050

Fleta Solomon, Managing Director
Little Green Pharma

E: fleta@lgpharma.com.au

M: +41 782 260 200

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility in Western Australia and an exclusive partnership with a GMP-licensed pharmaceutical manufacturer for the production of its own-branded range of medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com